A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study was published in the 30 September 2011 issue of the Journal “Cell” [I.F: 33.116] by Prof Daley GQ, Zhu H, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Regenerative therapy for DM: Ars2 (arsenite-resistance protein 2/Serrate RNA effector molecule homolog) promotes an insulin-sensitized state via up regulation of reprogramming protein Lin28.
Significance: Prof. Daley GQ and his team members have shown that loss of Lin28 promotes insulin resistance and glucose intolerance. The study presented here suggests, for the first time, that Ars2, by increasing the expression of its target gene, it may increase the expression of RNA-binding protein Lin-28, and thereby promote insulin sensitivity. Thus, pharmacological formulations encompassing ” Ars2 activators” may be used to treat DM.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How Ars2 increases the expression of Lin28
To cite: Boominathan, Regenerative therapy for DM: Ars2 (arsenite-resistance protein 2/Serrate RNA effector molecule homolog) promotes an insulin sensitized state via up regulation of reprogramming protein Lin28, 31/March/2015, 7.39 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation